MME and pulmonary arterial hypertension: While isolated angiotensin receptor blocking has not shown much improvements in PAH, simultaneous targeting of the RAAS and the NP system via combined angiotensin receptor blocking and neprilysin inhibition with Sacubitril/Valsartan (Sac/Val) has been shown to result in reduced RV pressures, RV hypertrophy, and pulmonary vascular wall thickness, in addition to maintained stroke volume and improved organ-level contractile and relaxation function (Clements et al., 2019; Sharifi Kia et al., 2020).